PEGylated talazoparib

N/A

Report date: 2024/10/30 15:18:09

Base Information

Drug NamePEGylated talazoparib
Drug Alias Namelong-acting PEG-talazoparibPEGylated talazoparibPLX376PLX-376
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursSarcoma, Ewing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProlynx Inc
China Registration ClassN/A

Develop Information

Active CompaniesProlynx Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSarcoma, Ewing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A